Correlation between TGF-ß1 and p21 (WAF1/CIP1) expression and prognosis in resectable invasive ductal carcinoma of the pancreas

Pancreas

Volumn 22, Issue 4, 2001, Pages 341-347

  Hashimoto, Koji ^a   Nio, Yoshinori ^a   Sumi, Shoichiro ^a   Toga, Tomoko ^a   Omori, Hiroshi ^a   Itakura, Masayuki ^a   Yano, Seiji ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

P21; Pancreatic cancer; TGF 1

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P21; TRANSFORMING GROWTH FACTOR BETA1; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PANCREAS CARCINOMA; PANCREAS RESECTION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; GENE EXPRESSION; GENETICS; MIDDLE AGED; MORTALITY; PANCREAS TUMOR;

ADULT; AGED; CARCINOMA, PANCREATIC DUCTAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PANCREATECTOMY; PANCREATIC NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TRANSFORMING GROWTH FACTOR BETA;

EID: 0034744458     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-200105000-00002     Document Type: Article

References (53)

1. The transforming growth factor-ß family
2. Transforming growth factor-ß: Recent progress and new challenges
3. Transforming growth factor-ß
4. Immunohistochemical staining for transforming growth facto ß1 associates with disease progression in human breast cancer
5. Transforming growth factor ßl expression in human colorectal tumors: An independent prognostic marker in a subgroup of poor prognosis patient
6. Transforming growth factor-ß isoforms expression in pulmonary adenocarcinomas as prognostic markers: An immunohistological study of one hundred and twenty patients
7. Role of transforming growth factor-ß1 in invasion and metastasis in gastric carcinoma
8. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of Gl cyclin-dependent kinases
9. p21 is a universal inhibitor of cyclin kinases
10. WAF1, a potential mediator of p53 tumor suppression
11. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis
12. Transforming growth factor ßl can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells
13. Transforming growth factor ß induces the cyclin-dependent kinase inhibitor p21 trough a p53-independent mechanism
14. Sensitivity to transforming growth factor ß1-induced growth arrest is common in human squamous cell carcinoma cell lines: c-MYC down-regulation and p21waf1 induction are important early events
15. Potential role of WAF1/Cip1/p21 as a mediator of TGF-ß cytoinhibitory effect
16. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving?
17. Analysis of p53, p21WAF1, and TGF-ß1 in human ductal adenocarcinoma of the pancreas: TGF-ß1 protein expression predicts longer survival
18. Enhanced expression of transforming growth factor ß isoforms in pancreatic cancer correlates with decreased survival
19. Expression of transforming growth factor ßl (TGFß1) and its receptors in pancreatic duct cell carcinoma and in chronic pancreatitis
20. Comparative significance of p53 and WAF/1-p21 expression on the efficacy of adjuvant chemotherapy for resectable invasive ductal carcinoma of the pancreas
21. Production of transforming growth factor alpha in human pancreatic cancer cells: Avoidance for a superagonistic autocrine cycle
22. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increase in the levels of epidermal growth factor and transforming growth factor alpha
23. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness
24. Clinicopathological significance of epidermal growth factor and its receptor in human pancreatic cancer
25. bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: Association with clinical outcome
26. Clinical contribution of bcl-2, p53 and K-67 proteins in pancreatic ductal adenocarcinoma
27. Bax but not bcl-2, influences the prognosis of human pancreatic cancer
28. Ki-ras point mutation and p53 expression in human pancreatic cancer: A comparative study among Chinese, Japanese, and Western
29. Signal transduction of the TGF-ß superfamily by Smad proteins
30. DPC4, a candidate tumor-suppressor gene at 18q21.1
31. Ligand induced upregulation of the type II transforming growth factor (TGF-ß) receptor enhances TGF-ß responsiveness in COLO-357 cells
32. Transforming growth factor-ß responsiveness in DPC4/SMAD4-null cancer cells
33. Tumor suppression by p21/WAF1
34. p21/WAF1 expression in human colorectal carcinoma: Association with p53, transcription factor AP-2 and prognosis
35. p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer
36. p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis
37. p21(Waf1/Cip1) and p53 protein expression in breast cancer
38. p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung
39. Loss of p21WAF1/CIP1 expression correlates disease progression in gastric carcinoma
40. Expression of p21(WAF1/ CIP1) protein in clinical thyroid tissues
41. WAF1/ CIP1 protein expression in human breast tumors
42. Expression of cyclins A and D and p21 (waf1/cip1) proteins in renal cell cancer and their relation to clinicopathological variables and patient survival
43. Protein expression of p53, p21WAF1, and Rb as prognostic indicators in patients with surgically treated hepatocellular carcinoma
44. Nuclear accumulation of p53 correlates significantly with clinical features and inversely with the expression of the cyclin-dependent kinase inhibitor p21WAF1/CIP1 in pancreatic cancer
45. TGF ß inhibition of Cdk4 synthesis is linked to cell cycle arrest
46. Transforming growth factor ß effects on expression of G1 cyclins and cyclin-dependent protein kinases
47. Negative regulation of G1 in mammalian cells: Inhibition of cyclin E-dependent kinase by TGF-ß
48. p151NK4B is a potential effector of TGF-ß-induced cell cycle arrest
49. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals
50. p27, a novel inhibitor of Gl cyclin-Cdk protein kinase activity, is related to p21
51. Absence of WAF1 mutations in a variety of human malignancies
52. Absence of a mutation of the p21/WAF1 gene in human lung and pancreatic cancers